Determination of Surface Visible Residue Limits on Pharmaceutical Plant Equipment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Determination of Surface Visible Residue Limits on Pharmaceutical Plant Equipment
The minimum amount of residue that can be visually detected on a surface, i.e., visible residue limit (VRL), is demonstrated for a small number of active pharmaceutical ingredients (APIs) on a range of different surface materials typically found in API and drug product manufacturing plants.


Pharmaceutical Technology
Volume 37, Issue 2

Results and discussion


Table I: Visible residue limit (VRL) data for active pharmaceutical ingredients (APIs) on surface materials of different composition.
Results from the inspections of the plates are summarized in Table I. The observations were generally consistent between the various observers, with all observers in each case reporting the same conclusion. The residue was considered to be above the VRL only if all observers could detect a residue. In the few instances where a residue was noted by some, but not all of the observers, the results were indicated as "barely detectable." Where none of the observers could detect a residue, the result was recorded as "not detected."

Regarding visualization of contamination, three of the APIs dried on the metal to leave a residue in the form of an approximately even, reddish-brown tarnish. All of the other materials on all surfaces dried to a residue that had the appearance of an evident white powder. This type of coverage was generally not uniformly distributed on the surface and instead appeared as many dried droplets or larger areas. This type of coverage was, however, shown in a separate activity involving deliberate soiling of an actual plant equipment as to how the contamination was deposited in the plant. Accordingly, the plate studies were considered representative for an assessment of VRLs in the processing equipment.

The following results were recorded regarding the VRLs:
  • Observations for clear glass, also blue and white enamel, were consistent across all of the different compounds tested in this study. VRLs for these materials of construction were lowest for blue enamel and clear glass, viewed from either side of the glass, with all test compounds visible at 10 g/dm2 . Two of the APIs were tested at lower loadings on these surfaces and were visible at 5 g/dm2 and also at 2 g/dm2 with the aid of an additional light source. The absolute VRL thresholds were not determined on these surfaces for any of these materials because they were out of the scope of this study.
  • White PTFE exhibited comparatively the highest VRL, with some materials only being detected at 400 g/dm2 with the aid of additional light source. On this surface, there was significant variance between materials.
  • On metal, there was variability between VRLs across the range of the test compounds. There was also a clear correlation between metal-surface roughness and the VRL. Although there were differences in the absolute VRLs for each material, the VRLs for all test compounds increased with increasing surface roughness. Five of the six APIs were visible on the highly polished surface of 0.0 m roughness, at 10 g/dm2 , whereas only one was visible at 100 g/dm2 on 1.1-m surface roughness. There was also some variation in the rate of increase in difficulty in visualizing each compound with increasing surface roughness.
  • The contamination was invariably easier to see with the additional portable light source and more obvious when viewed from an angle of approximately 30–60. In agreement with previous studies, viewing from directly above the surface was not optimal due to surface reflections.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here